Glembatumumab vedotin
Product Specifications
UNSPSC Description
Glembatumumab vedotin (CDX-011) is an ADC (antibody-drug conjugates (ADCs)) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects[1].
Target Antigen
Antibody-Drug Conjugates (ADCs); Microtubule/Tubulin
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/glembatumumab-vedotin.html
Solubility
10 mM in DMSO
Smiles
[Glembatumumab vedotin]
Molecular Weight
150000 (average)
References & Citations
[1]Christopher H Keir, et al. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther. 2012 Feb;12(2):259-63. |[2]Vincent A Pollack, et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol. 2007 Aug;60(3):423-35. |[3]Michael Roth, et al. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatr Blood Cancer. 2016 Jan;63(1):32-8.
Shipping Conditions
Dry Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-141604/Glembatumumab-vedotin-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-141604/Glembatumumab-vedotin-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
1182215-65-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
